Press Room

Press Room

  • June, 2017
    NLS touts Mazindol's efficacy as it takes on ADHD market

    READ THE NEWS

  • June, 2017
    NLS phase II results advance effort to carve out alternative ADHD drug niche

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS touts positive ADHD data, plots late-stage tests

    READ THE NEWS

  • June, 2017
    Potential Treatment for ADHD Yields Positive Phase II Data

    READ THE NEWS

  • June, 2017
    NLS Pharma’s new ADHD compound could break the focus of the field

    READ THE NEWS

  • June, 2017
    The Handoff: Your Week in Neurology News

    READ THE NEWS

  • June, 2017
    Is ADHD a sleep disorder? Stimulant drug improves symptoms

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS

  • June, 2017
    NLS Pharma Pins Hopes On Ex-Obesity Drug For ADHD

    READ THE NEWS

  • June, 2017
    Mid-stage data show promise for mazindol C-R

    READ THE NEWS

  • June, 2017
    NLS Pharma’s results offer hope of changing ADHD landscape

    READ THE NEWS

  • June, 2017
    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    READ THE NEWS